Abstract 1441P
Background
The accurate detection of lymph node metastasis (LNM) in early gastric cancer (EGC) remains a challenge, conventional radical gastrectomy may not be warranted for EGC patients with a low LNM risk and a favorable prognosis. This study aims to construct a risk prediction model of lymph node metastasis based on clinicopathologic features, tumor budding, convolutional neural network, and machine learning in early gastric cancer.
Methods
Clinicopathological features and tumor budding (TB) were assessed using the image recognition software Qupath. There was a total of 1523471 patches, 260998 patches, and 166594 patches from three patient cohorts that were retrospectively analyzed. Convolutional neural networks (CNNs) were used for deep transfer learning to classify patches and extract features. LASSO regression and multiple machine learning algorithms were employed to combine CNN features with clinicopathological features. The risk prediction model was also verified in two independent validation cohorts.
Results
Among 200 patients, LNM incidence was 27.14% in the training cohort, 15.15% in the internal validation cohort, and 14.82% in the external validation cohort. Multivariate analysis identified pathological T stage and ITBCC-TB grade as independent LNM risk factors (p < 0.05). The Resnet152 CNN model demonstrated excellent performance with AUC values of 0.995, 0.988, and 0.965 in the training, internal validation, and external validation cohorts, respectively. The CNN-ML model using Gradient Boosting exhibited superior predictive capacity, with AUC values of 0.901 (95% CI 0.844-0.957), 0.871 (95% CI 0.726-0.999), and 0.804 (95% CI 0.555-0.999) in the training and two independent validation cohorts.
Conclusions
Pathological T stage and ITBCC-TB grade were identified as independent risk factors for LNM in EGC. The integration of clinicopathological features, image recognition, and deep transfer learning using CNNs resulted in a highly accurate predictive model for LNM in EGC. This model will provide valuable insights into the development of a more comprehensive and individualized approach to managing EGC, thereby improving the quality of care for affected patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1456P - First in human phase I/II trial of claudin 18.2 ADC RC118 in patients with advanced gastric/gastroesophageal junction cancer
Presenter: Tianshu Liu
Session: Poster session 18
1457P - Tumor immune microenvironment subtypes of esophageal squamous cell carcinoma and their strong ability to predict the efficacy of neoadjuvant immunotherapy
Presenter: Guangyu Yao
Session: Poster session 18
1458P - Impact of 68Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) on staging and treatment in patients with gastric cancer
Presenter: Shunyu Zhang
Session: Poster session 18
Resources:
Abstract
1459P - Long-term management and outcomes in gastroesophageal cancer in Norway
Presenter: Aleksander Kolstad
Session: Poster session 18
1460P - Association between effectiveness of treatment with curative intent and outcomes of first-line systemic therapy in metachronous metastatic esophagogastric cancer
Presenter: Denice Kamp
Session: Poster session 18
1462P - A pilot study of hypoxia as a potential resistance mechanism to PD-1 checkpoint blockade therapy in neoadjuvant treatment of esophageal squamous cell carcinoma (HYPERION)
Presenter: Bin Li
Session: Poster session 18
1463P - The presence of liver metastases is associated with systemic immune suppression in gastroesophageal cancer
Presenter: Sebastiaan Siegerink
Session: Poster session 18
1464P - Chemo-radiation alone associated with higher risk of death compared to chemo-radiation plus surgery in esophageal squamous cell carcinoma
Presenter: Brian Housman
Session: Poster session 18
1465P - Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapy
Presenter: Takeru Wakatsuki
Session: Poster session 18